The IC50 values of HER2 + cells (SK-BR-3 and HCC1954) were intermediate (ranging from 0.05 μM to 0.5 μM), suggesting that patients with HER2 + breast cancer might benefit from MLN9708-containing therapy. Here, ERBB2 is linked to breast carcinoma.